In a first, scientists have identified promising drug candidates that can permanently disable a key cancer protein once deemed untreatable—a discovery that could revolutionize cancer treatment.

Lariocidin hits drug-resistant bacteria where others fail — by hijacking the ribosome at a new site, bypassing defences, and opening the door to a new generation of antibiotics. Lariocidin, a ...

Identifying crucial peptide sequences involved in IRF5–protein interactions is essential. The development of specific small-molecule inhibitors to disrupt these processes offers a promising strategy ...

Their dysregulation has been implicated in numerous diseases, particularly cancer. This is where kinase inhibitors come into play. Kinases have become one of the most extensively targeted enzymes in ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...

Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering peptides that bind selectively and irreversibly within cells, permanently blocking ...

Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering peptides that bind selectively and irreversibly within cells, permanently blocking ...

Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering peptides that bind selectively and irreversibly within cells, permanently blocking cJun ...

Their previous work identified reversible inhibitors of cJun, but this latest work builds on that by discovering peptides that bind selectively and irreversibly within cells, permanently blocking ...

ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early ...